Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Inc.’s Subsidiaries Soluble Biotech Inc. and TumorGenesis Inc. are both constructing new GMP labs
MINNEAPOLIS , June 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , an AI-driven oncology and drug discovery company, announced today that two of their wholly owned subsidiaries, Soluble Biotech Inc. and TumorGenesis Inc. are both expanding their unique services by completing the
View HTML
Toggle Summary Predictive Oncology Announces Closing of $21.34 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
MINNEAPOLIS , June 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the closing of
View HTML
Toggle Summary Predictive Oncology Announces $21.34 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
MINNEAPOLIS , June 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into
View HTML
Toggle Summary Predictive Oncology Inc. to Attend BIO DIGITAL, the World’s Largest Biotech Partnering Experience
MINNEAPOLIS , June 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its three wholly owned subsidiaries, Helomics , TumorGenesis and
View HTML
Toggle Summary Predictive Oncology Inc.’s Wholly Owned Subsidiary, TumorGenesis, Partners with Cellevate AB
MINNEAPOLIS , May 20, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , an artificial intelligence driven oncology and drug discovery company, announced today that its wholly owned subsidiary, TumorGenesis ( TumorGenesis.net ), has partnered a deal with the Swedish firm Cellevate AB (
View HTML
Toggle Summary Predictive Oncology Reports Financial Results for Quarter Ended March 31, 2021 and Provides Business Update
MINNEAPOLIS , May 12, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended March 31, 2021 and provided an
View HTML
Toggle Summary Predictive Oncology Inc. Announces Newest Board Member
MINNEAPOLIS , April 27, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce today their newest Board Member Dr. Christina Jenkins . Dr.
View HTML
Toggle Summary Predictive Oncology Inc. Announces New CEO
MINNEAPOLIS , March 23, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is excited to announce today that they have appointed J.
View HTML
Toggle Summary Predictive Oncology Reports Year End 2020 Financial Results, Provides Business Update
MINNEAPOLIS , March 15, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) – Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the year ended
View HTML
Toggle Summary Predictive Oncology’s, Skyline Medical Division, Developing Generation 3 Direct-to-Drain Automated Fluid Waste Management System
MINNEAPOLIS , March 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its Skyline Medical Division is renewing developing a new Generation
View HTML